Development Update


 

TIDMMMG 
 
 
Medical Marketing Int'l Group PLC 
05 June 2009 
 
? 
 DEVELOPMENT UPDATE 
 
 
5 June 2009 - Medical Marketing International Group plc ("MMI" or the "Company") 
(AIM:MMG), the life sciences company focused on the development of drugs for 
cancer, today announces that Professor Christian Ottensmeier of the University 
of Southampton will make a presentation relating to a University of Southampton 
Phase I/II clinical study in prostate cancer entitled "Epitope specific DNA 
fusion vaccination for prostate cancer - durable induction of CD8 responses" at 
the 7th International Cancer Immunotherapy (CIMT) meeting 2009 in Mainz, 
Germany. The Company has been informed the presentation will not contain any 
information relating to prostate specific antigen measurement (PSA), a marker 
frequently used to monitor prostate cancer disease progression. 
 
 
Enquiries: 
 
 
+-----------------------------------------+-----------------------------------------+ 
| Medical Marketing International Group   | Tel: +44 (0) 1223 477 677               | 
| plc                                     |                                         | 
| Phil Cartmell, Non-executive Chairman   |                                         | 
| Mark Burton, Chief Technical Officer    |                                         | 
| Rob Sprawson, Chief Financial Officer   |                                         | 
+-----------------------------------------+-----------------------------------------+ 
|                                         |                                         | 
+-----------------------------------------+-----------------------------------------+ 
| FinnCap                                 | Tel: +44 (0)20 7600 1658                | 
| Sam Smith/Charlie Cunningham            |                                         | 
+-----------------------------------------+-----------------------------------------+ 
|                                         |                                         | 
+-----------------------------------------+-----------------------------------------+ 
| Financial Dynamics                      | Tel: +44 (0)20 7831 3113                | 
| Emma Thompson                           |                                         | 
+-----------------------------------------+-----------------------------------------+ 
 
 
About MMI 
Medical Marketing International Group plc ("MMI") is a life sciences company 
that identifies, acquires and develops world-class compounds and technologies 
for the treatment of cancer. The Company manages the preclinical and early 
clinical development of drug candidates before pursuing licensing partners to 
manage late-stage development. Please visit www.mmigroup.co.uk for further 
information. 
 
 
Notwithstanding the inclusion on this release by MMI of a website address and/or 
another electronic address, MMI does not accept any notices or any other 
documents or communication via its website or other electronic address. All such 
notices, documents or communication shall be in hard copy format only. 
Accordingly the provisions of section 333 Companies Act 2006 allowing persons to 
communicate with MMI electronically shall not apply to MMI. 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRAUUUAAQUPBGQC

Medical Mktg (LSE:MMG)
過去株価チャート
から 5 2024 まで 6 2024